Ionis Pharmaceuticals (NASDAQ:IONS) vs. Dyne Therapeutics (NASDAQ:DYN) Financial Survey

Dyne Therapeutics (NASDAQ:DYN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

Dyne Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Institutional and Insider Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 14.1% of Dyne Therapeutics shares are held by company insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Dyne Therapeutics and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-66.17%	-56.35%
Ionis Pharmaceuticals	-26.45%	-44.26%	-8.65%

Valuation & Earnings

This table compares Dyne Therapeutics and Ionis Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$317.42 million	($3.66)	-5.54
Ionis Pharmaceuticals	$705.00 million	18.77	-$453.90 million	($1.69)	-48.33

Dyne Therapeutics has higher earnings, but lower revenue than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Dyne Therapeutics and Ionis Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	3	10	4	2.94
Ionis Pharmaceuticals	1	3	17	1	2.82

Dyne Therapeutics presently has a consensus target price of $35.47, indicating a potential upside of 74.88%. Ionis Pharmaceuticals has a consensus target price of $84.15, indicating a potential upside of 3.02%. Given Dyne Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Dyne Therapeutics is more favorable than Ionis Pharmaceuticals.

Summary

Dyne Therapeutics beats Ionis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.